Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 5/20 | 0.42 |
| ▸ | CCR2 | P41597 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | F10 | P00742 | 6/20 | 0.36 |
| ▸ | FPR2 | P25090 | 4/20 | 0.36 |
| ▸ | FPR1 | P21462 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4683395 | 0.84 | CCR1 (0.40) | CCR1CCR2ALDH1A1F10FPR2 | |
| SCHEMBL4490491 | 0.83 | F10 (0.36) | ALDH1A1F10FPR2FPR1 | |
| SCHEMBL20581625 | 0.80 | FPR2 (0.46) | CCR1CCR2F10FPR2FPR1 | |
| SCHEMBL20581623 | 0.80 | FPR2 (0.46) | CCR1CCR2F10FPR2FPR1 | |
| SCHEMBL28395450 | 0.79 | CCR1 (0.40) | CCR1CCR2ALDH1A1F10FPR2 | |
| SCHEMBL28395449 | 0.79 | CCR1 (0.40) | CCR1CCR2ALDH1A1F10FPR2 | |
| SCHEMBL6860135 | 0.78 | CCR1 (0.39) | CCR1CCR2ALDH1A1TSHRHPGD | |
| SCHEMBL4490944 | 0.78 | F10 (0.54) | ALDH1A1F10FPR2FPR1HPGD | |
| SCHEMBL4478595 | 0.76 | F10 (0.55) | F10FPR2FPR1 | |
| SCHEMBL4487629 | 0.76 | ROCK2 (0.45) | ALDH1A1FPR2FPR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1337251-B1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2008-08-20 | — | — | EP | disclosed |
| US-6951872-B2 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| US-6858616-B2 | Nitrogen containing heterobicycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-02-22 | — | — | US | disclosed |
| EP-1140941-B1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2004-10-20 | — | — | EP | disclosed |
| US-6790845-B2 | HAVING AN ATTACHED NON-AROMATIC HETEROCYCLIC RING | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-14 | — | — | US | disclosed |
| US-20040132718-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | JACOBSON IRINA C (US) | 2004-07-08 | — | — | US | disclosed |
| US-6710058-B2 | USE AS ANTICOAGULANT AGENTS FOR THERAPY AND PROPHYLAXIS OFTHROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-23 | — | — | US | disclosed |
| EP-1337251-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-08-27 | — | — | EP | disclosed |
| US-20030087909-A1 | Fused heterocyclic inhibitors of factor Xa | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-05-08 | — | — | US | disclosed |
| US-20030069237-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | FEVIG JOHN M (US) | 2003-04-10 | — | — | US | disclosed |
| WO-2002102380-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-05 | — | — | US | disclosed |
| WO-2002080853-A2 | FUSED HETEROCYCLIC INHIBITORS OF FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-17 | — | — | WO | disclosed |
| US-6413980-B1 | INHIBITORS OF TRYPSIN-LIKE SERINE PROTEASE ENZYMES; ANTICOAGULANTS; THROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-07-02 | — | — | US | disclosed |
| EP-1140941-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | Du Pont Pharmaceuticals Company (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039131-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069237-A1 | Nitrogen containing heterobicycles as factor Xa inhibitors | F12, F11, F10 | CCR1 4311/4885CCR2 4362/4885ALDH1A1 4792/4885 |
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | CCR1 434/4885CCR2 1165/4885ALDH1A1 2263/4885 |
| US-20030087909-A1 | Fused heterocyclic inhibitors of factor Xa | TFPI, F11, F12 | CCR1 3879/4885CCR2 4483/4885ALDH1A1 2451/4885 |
| US-20040132718-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | CCR1 434/4885CCR2 1165/4885ALDH1A1 2263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.